NEW YORK – Nomic Bio on Tuesday said it signed a collaboration agreement with the Parker Institute for Cancer Immunotherapy (PICI) to identify protein biomarkers associated with immunotherapy response among patients with various types of cancer.
Using its nELISA protein quantification platform, Nomic will profile blood samples from PICI's Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets (RADIOHEAD) study for signals associated with patient response to therapy, survival rates, and the likelihood of developing immune-related adverse events. Montreal-based Nomic and PICI plan to publish data from the study beginning in early 2025.
In the RADIOHEAD study, investigators gathered samples from more than 1,000 patients on standard-of-care immune checkpoint inhibitor treatment at 52 community hospitals around the US to identify drivers of immune-related adverse events and clinical response.
"By characterizing the soluble signaling molecules of our longitudinal patient samples, we aim to elucidate the communication pathways among immune cells in response to disease states and treatments," Tarak Mody, PICI's chief business officer, said in a statement.
PICI, which is headquartered in San Francisco, has previously partnered with Guardant Health and Boston Gene to further explore biomarkers of response and adverse effects within RADIOHEAD.